Logo image of MRNA

MODERNA INC (MRNA) Stock Price, Quote, News and Overview

NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock - Currency: USD

26.76  +0.5 (+1.9%)

After market: 26.82 +0.06 (+0.22%)

MRNA Quote, Performance and Key Statistics

MODERNA INC

NASDAQ:MRNA (5/27/2025, 8:00:01 PM)

After market: 26.82 +0.06 (+0.22%)

26.76

+0.5 (+1.9%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High158.82
52 Week Low23.15
Market Cap10.35B
Shares386.62M
Float358.47M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30/bmo
IPO12-07 2018-12-07


MRNA short term performance overview.The bars show the price performance of MRNA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

MRNA long term performance overview.The bars show the price performance of MRNA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of MRNA is 26.76 USD. In the past month the price decreased by -2.55%. In the past year, price decreased by -81.23%.

MODERNA INC / MRNA Daily stock chart

MRNA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.08 328.06B
AMGN AMGEN INC 13.46 150.26B
GILD GILEAD SCIENCES INC 14.09 135.70B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.53B
REGN REGENERON PHARMACEUTICALS 13.61 65.13B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.83B
ARGX ARGENX SE - ADR 98.77 35.40B
ONC BEIGENE LTD-ADR 6.1 25.76B
BNTX BIONTECH SE-ADR N/A 23.69B
NTRA NATERA INC N/A 21.46B
SMMT SUMMIT THERAPEUTICS INC N/A 19.04B
BIIB BIOGEN INC 8.12 18.81B

About MRNA

Company Profile

MRNA logo image Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 5,800 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Company Info

MODERNA INC

325 Binney Street

Cambridge MASSACHUSETTS 02139 US

CEO: Stephane Bancel

Employees: 5800

MRNA Company Website

MRNA Investor Relations

Phone: 16177146500

MODERNA INC / MRNA FAQ

What is the stock price of MODERNA INC today?

The current stock price of MRNA is 26.76 USD. The price increased by 1.9% in the last trading session.


What is the ticker symbol for MODERNA INC stock?

The exchange symbol of MODERNA INC is MRNA and it is listed on the Nasdaq exchange.


On which exchange is MRNA stock listed?

MRNA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MODERNA INC stock?

33 analysts have analysed MRNA and the average price target is 46.68 USD. This implies a price increase of 74.45% is expected in the next year compared to the current price of 26.76. Check the MODERNA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MODERNA INC worth?

MODERNA INC (MRNA) has a market capitalization of 10.35B USD. This makes MRNA a Large Cap stock.


How many employees does MODERNA INC have?

MODERNA INC (MRNA) currently has 5800 employees.


What are the support and resistance levels for MODERNA INC (MRNA) stock?

MODERNA INC (MRNA) has a support level at 26.67 and a resistance level at 27.47. Check the full technical report for a detailed analysis of MRNA support and resistance levels.


Is MODERNA INC (MRNA) expected to grow?

The Revenue of MODERNA INC (MRNA) is expected to decline by -34.88% in the next year. Check the estimates tab for more information on the MRNA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MODERNA INC (MRNA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MODERNA INC (MRNA) stock pay dividends?

MRNA does not pay a dividend.


When does MODERNA INC (MRNA) report earnings?

MODERNA INC (MRNA) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of MODERNA INC (MRNA)?

MODERNA INC (MRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.73).


What is the Short Interest ratio of MODERNA INC (MRNA) stock?

The outstanding short interest for MODERNA INC (MRNA) is 16.8% of its float. Check the ownership tab for more information on the MRNA short interest.


MRNA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MRNA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MRNA. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRNA Financial Highlights

Over the last trailing twelve months MRNA reported a non-GAAP Earnings per Share(EPS) of -8.73. The EPS increased by 44.29% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.42%
ROE -33.35%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%17.92%
Sales Q2Q%-35.33%
EPS 1Y (TTM)44.29%
Revenue 1Y (TTM)-38.35%

MRNA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 64% to MRNA. The Buy consensus is the average rating of analysts ratings from 33 analysts.

For the next year, analysts expect an EPS growth of -12.35% and a revenue growth -34.88% for MRNA


Ownership
Inst Owners73.88%
Ins Owners5.45%
Short Float %16.8%
Short Ratio6.17
Analysts
Analysts64.24
Price Target46.68 (74.44%)
EPS Next Y-12.35%
Revenue Next Year-34.88%